Clinical trials: Mpox (Monkeypox)
Mpox
Mpox Comprehensive Assessment for Responsive Immunisation in Emergency Outbreaks
The MPXV CARE study principally aims to use clinical and epidemiology data to target specific individuals willing and able to provide appropriate and proportionate biological samples to develop novel immune diagnostics that…
- Trial name
- MPOX CARE (NCT06887556)
- Testing
- ELISA, Lateral flow assay
- Where
- Rwanda
- Volunteers
- 650 people, healthy volunteers welcome
- Sponsor
- University of Birmingham
Monkeypox
A Clinical Study Investigating the Safety and Immune Responses After Immunization With Investigational Monkeypox Vaccines
This was a dose-escalation, Phase I/II study evaluating the safety, tolerability, reactogenicity and immunogenicity of the investigational RNA-based multivalent vaccine candidate BNT166a for active immunization against monkeypox…
- Trial name
- NCT05988203
- Testing
- BNT166a
- Where
- 9 sites in United States, United Kingdom
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
Mpox (Monkeypox)
Epidemiological and Clinical Characteristics of Human Mpox Outbreak in Equateur Province in the Democratic Republic of Congo (Part3)
The goal of this study is to evaluate the effectiveness of smallpox vaccination administered before the global eradication of smallpox against currently circulating mpox in the Democratic Republic of the Congo.
- Trial name
- NCT06984705
- Where
- Democratic Republic of the Congo
- Volunteers
- 144 people
- Sponsor
- Osaka Metropolitan University
Smallpox, Monkeypox
Tecovirimat (ST-246) Treatment for Orthopox Virus Exposure
The purpose of this clinical protocol is to treat individuals with Tecovirimat after exposure to orthopox viruses.
- Trial name
- NCT02080767
- Testing
- Tecovirimat
- Sponsor
- U.S. Army Medical Research and Development Command
Monkeypox
Mpox Prospective Observational Cohort Study
The goal of this multicentre prospective observational cohort study is to shed light on the following unknowns: 1. The clinical manifestations of Mpox infection since the 2022 outbreak in Canada. 2.
- Trial name
- MPOCS (NCT06291259)
- Where
- 3 sites in Canada
- Volunteers
- 250 people
- Sponsor
- Unity Health Toronto
Mpox
Validation of SDS-EDTA-Treated Chromatography Paper Strips for Mpox Sampling and Transport in DRC
The objective of this prospective paired diagnostic comparison study is to evaluate the diagnostic yield and field applicability of SDS-EDTA-treated chromatography paper strips for the collection, transport, and laboratory…
- Trial name
- NCT07634081
- Testing
- SDS-EDTA-treated chromatography strip
- Where
- Democratic Republic of the Congo
- Volunteers
- 150 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Mpox (Monkeypox)
Tecovirimat for Treatment of Monkeypox Virus - Study Extension Providing Standard of Care Only
The purpose of the PALM007 extension is to further characterize the clinical and natural history of mpox, and to provide standard of care (SOC) during the ongoing outbreaks.
- Trial name
- NCT06721585
- Testing
- Tecovirimat Oral Capsule [Tpoxx], Standard of Care (SOC)
- Where
- 2 sites in Democratic Republic of the Congo
- Volunteers
- 328 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Monkeypox
Viral Clearance and Epidemiological Characteristics in Patients With Monkeypox
The present observational study has been designed to understand the dynamics of viral clearance amongst patients with confirmed monkeypox, by quantifying monkeypox viral load in different specimens trough time, to better inform…
- Trial name
- MoViE (NCT05476744)
- Where
- 5 sites in Spain
- Volunteers
- 77 people
- Sponsor
- Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia
COVID-19, SARS-CoV-2 Viraemia
Neutralizing Power of Serum Antibodies - 2
Severe forms of COVID-19 and Monkeypox affect immunocompromised and comorbid individuals. Vaccination and monoclonal antibody therapies induce neutralizing antibodies.
- Conditions
- COVID-19, SARS-CoV-2 Viraemia, Monkey Pox, Vaccination
- Trial name
- PNAS-2 (NCT07085611)
- Testing
- Sample collection (blood and optional nasal swab)
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Centre Hospitalier Régional d'Orléans
Emerging Infectious Diseases, COVID-19
Smart Analysis and Decision-Making for Emerging Infectious Diseases
Emerging infectious diseases, such as COVID-19, mpox, and dengue fever, are characterized by rapid transmission, wide impact, and high uncertainty, posing ongoing threats to global public health.
- Conditions
- Emerging Infectious Diseases, COVID-19, Influenza, Mpox (Monkeypox)
- Trial name
- SMART-ID (NCT07678619)
- Testing
- Multi-Agent Integrated Smart Toolkit for Emerging Infectious Diseases, Routine Practices
- Where
- China
- Volunteers
- 108 people
- Sponsor
- Peking University
Monkeypox
Assessment of Safety Profile of MVA-BN Vaccine in the PALM-007 Study in DRC
The goal of this observational study is to monitor and assess the safety profile of the MVA-BN vaccine among staff and study personnel of the PALM-007 study in the Democratic Republic of the Congo.
- Trial name
- NCT05734508
- Testing
- MVA-BN vaccine
- Where
- 3 sites in Democratic Republic of the Congo
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Monkeypox, Mpox (Monkeypox)
Ocular Complications of Mpox in the Democratic Republic Congo
This is an observational study in which patients diagnosed with mpox will be enrolled, will undergo standard ophthalmological examinations of their eyes to see if there are any complications of mpox.
- Trial name
- MPOX-EYE (NCT06579885)
- Where
- Democratic Republic of the Congo
- Volunteers
- 320 people
- Sponsor
- Institute of Tropical Medicine, Belgium
Monkey Pox, Monkey Diseases
Follow-up of People at Risk of Monkeypox Infection: a Prospective Cohort Study
Since one month (first case confirmed the 05/06/2022), some cases of non-imported were reported by Portuguese and British authorities then in several Europeans countries, the US and the Canada.
- Trial name
- MonkeyVax (NCT05438953)
- Testing
- Vaccination with MVA vaccine ( IMVANEX® and JYNNEOS®)
- Where
- France
- Volunteers
- 164 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Mpox (Monkeypox), Vaccination
Phase 3 Infant Safety & Immunogenicity Trial of MVA-BN® in DRC
This Phase 3 double-blinded, randomized study aims to evaluate the safety and immunogenicity of the two-dose MVA-BN mpox vaccine regimen, administered subcutaneously, in infants and children aged 4 to 24 months in the Democratic…
- Conditions
- Mpox (Monkeypox), Vaccination, Immunogenicity, Safety
- Trial name
- PregInPoxVac (NCT06844487)
- Testing
- MVA-BN standard regimen, MVA-BN half-dose regimen
- Where
- Democratic Republic of the Congo
- Volunteers
- 344 people, healthy volunteers welcome
- Sponsor
- Jean-Pierre Van geertruyden
Monkey Pox
Assessing the Preparedness and Knowledge of Pharmacists in the Current Monkeypox Outbreak
General objective: to measure the preparedness of pharmacists and medical interns about monkeypox Specific objectives: to evaluate the level of knowledge among pharmacists and medical interns about monkeypox treatment and nature…
- Trial name
- NCT05543577
- Testing
- Questionnaire
- Where
- Egypt
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Beni-Suef University
Mpox (Monkeypox)
Looking for Asymptomatic Mpox in a Population at High Risk
Mpox is caused by a virus that can be spread through touching the affected skin of someone who has the infection, touching sheets or clothes that has been used by someone with the infection, or breathing in particles of virus…
- Trial name
- LAMP (NCT06353737)
- Where
- Canada
- Volunteers
- 450 people
- Sponsor
- Unity Health Toronto
Monkeypox
Efficacy/Effectiveness, Safety, and Immunogenicity of LC16m8 Mpox Vaccine in Colombia
Background: Mpox is a zoonotic disease caused by the mpox virus (MPXV). It has been endemic in West and Central African countries.
- Trial name
- MPOX-COL (NCT06223919)
- Testing
- LC16m8
- Where
- 3 sites in Colombia
- Volunteers
- 8,686 people, healthy volunteers welcome
- Sponsor
- Universidad Nacional de Colombia
Smallpox, Mpox
A Study to Investigate The Safety, Tolerability, And Immune Response of a Range of Doses of mRNA-1769 Compared With Placebo in Healthy Participants From ≥18 Years of Age to <50 Years of Age
The goal of this study is to assess the safety, tolerability and immunogenicity of mRNA-1769 in healthy adult participants.
- Trial name
- NCT05995275
- Testing
- mRNA-1769
- Where
- 12 sites in United Kingdom
- Volunteers
- 351 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Monkeypox (Mpox)
Prospective Follow-up After MVA-BN Booster Vaccination
POQS-Boosted is a prospective observational study during which individuals who received Booster vaccination against mpox with the MVA-BN vaccine will be invited to provide biological samples at multiple times over the course of…
- Trial name
- POQS-Boosted (NCT07342829)
- Where
- Belgium
- Volunteers
- 95 people, healthy volunteers welcome
- Sponsor
- Institute of Tropical Medicine, Belgium
Orthopoxviral Disease, Smallpox
Phase I Trial of an Investigational Small Pox Medication
The purpose of this study was to evaluate the pharmacokinetic parameters and safety of a single dose of ST-246 400mg Form I versus ST-246 400mg Form V capsules in fed normal healthy volunteers.
- Conditions
- Orthopoxviral Disease, Smallpox, Monkey Pox
- Trial name
- NCT00728689
- Testing
- ST-246 Days 1 - 3, ST-246 Days 11 - 13
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- SIGA Technologies